The country is also first in experimentation. On December 3, the summit between scientists
Representatives of the world’s leading pharmaceutical companies active in Huntington’s disease experimentation will meet with the best researchers in the field of rare diseases and with patients: all seated at the same virtual table for a unique opportunity of its kind on the progress in experimentation on the Huntington’s disease. This is what is organized by the Lirh Foundation, the Italian Huntington Research League, as part of its annual conference scheduled for Friday 3 December from 3 to 5.30 pm online. The Italian excellence in the study and experimentation on Huntington’s disease has been recognized worldwide thanks to the work of Lirh who sees how Scientific director Professor Ferdinando Squitieri, principal investigator of all clinical trials on Huntington carried out in Italy. During the conference, the developments on pridopidine, a molecule in phase III of experimentation also in Italy under the guidance of Prof. Squitieri, who obtained the designation of “fast track” by the Food and Drug Administration, will also be announced, a recognition that could accelerate and facilitate the time to market as an investigational drug. To illustrate the details during the Lirh conference will be Professor Michael R. Hyden, scientist and CEO of Prilenia. The conference will take place online on the Rafiky platform and will guarantee simultaneous translation from Italian into English. Dr Barbara D’Alessio, President of Lirh, Dr Simonetta Massafra, Head of Clinical Research Uoc Mendel Institute IRCSS Casa Sollievo della Sofferenza and Health Director of the CSS-Mendel Institute of Rome and Professor Ferdinando Squitieri, head of of the Research Unit on Huntington’s Disease of the IRCCS Casa Sollievo della Soflievo in San Giovanni Rotondo and the Mendel Institute in Rome. The conference will be attended by representatives of pharmaceutical companies with innovative therapies being tested: Michael A. Panzara for Wave Life Sciences, Daniel Leonard and Sara Ying for uniQure, Beth Borowsky for Novartis and Anu Bhattacharyya for PTC Therapeutics will illustrate the data that emerged from previous studies and the prospects for future experimentation. Researchers and patients will also be able to take part in the discussion with questions and insights by registering on the site www.lirh.it
December 3, 2021 (change December 3, 2021 | 02:43)
© Time.News